Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-60444 in adults with RSV infection following stem cell transplantation
2004-003657-99Phase 2Completed
- Sponsor
- Arrow Therapeutics
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) and upper respiratory infection (URI) comparing A-60444 with Placebo (2 arms). Primary endpoint: Reduction of viral load at 72 hours after initial dose. Started Feb 2005; status: completed.
02
Drugs
RSV-604
03
Conditions
respiratory syncytial virus disease (RSV)upper respiratory infection (URI)
Beyond the preview
Go deeper on 2004-003657-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003657-99.